Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Clinical and Laboratory Investigation

Review of the Chronology of Clinical Manifestations in 60 Patients with Behçet’s Disease

Alpsoy E.a · Donmez L.b · Bacanli A.a · Apaydin C.c · Butun B.d

Author affiliations

Departments of aDermatology, bPublic Health, cOphthalmology and dRheumatology, Akdeniz University School of Medicine, Antalya, Turkey

Related Articles for ""

Dermatology 2003;207:354–356

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Clinical and Laboratory Investigation

Received: November 29, 2002
Accepted: May 10, 2003
Published online: January 29, 2004
Issue release date: 2003

Number of Print Pages: 3
Number of Figures: 0
Number of Tables: 2

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM

Abstract

Background: The natural course of Behçet’s disease is not fully known. Objective: The aim of the present study was to determine the occurrence of the symptoms retrospectively in chronologic order in patients with Behçet’s disease, diagnosed according to the criteria of the International Study Group for Behçet’s Disease. Methods: A total of 60 consecutive patients (29 male and 31 female; aged 35.87 ± 9.84 years) were involved in the study. The symptoms of the disease were retrospectively recorded in the time order of the manifestations per patient. Results: Oral ulcer was the most commonly observed onset manifestation (51 of 60 patients: 85%), followed by genital ulcer (13 of 60 patients: 21.7%) and articular symptoms (10 of 60 patients: 16.7%). The duration between the oral ulcer and the fulfilment of diagnostic criteria was calculated to be 3.77 ± 4.43 years. The same duration was 2.50 ± 4.74 and 2.11 ± 3.44 years for genital ulcer and articular symptoms, respectively. The duration between the time point of fulfilment of diagnostic criteria and the diagnosis (2.83 ± 2.3 years) was found to be longer in female patients (3.2 ± 2.5 years). The duration was also longer in patients having only mucocutaneous lesions (3.18 ± 2.5 years) than in patients having serious organ involvement such as eye disease (1.63 ± 0.7 years; p < 0.05). Conclusion: Our study indicates that oral ulcer is the onset manifestation in the majority of the patients and the disease is often diagnosed with a delay of several years after the appearance of the onset sign.

© 2003 S. Karger AG, Basel


References

  1. Alpsoy E, Kodelja V, Goerdt S, Orfanos CE, Zouboulis CC: Serum of patients with Behçet’s disease induces classical (pro-inflammatory) activation of human macrophages in vitro. Dermatology 2003;206:225–232.
  2. International Study Group for Behçet’s Disease: Criteria for diagnosis of Behçet’s disease. Lancet 1990;335:1078–1080.
  3. O’Neill TW, Rigby AS, Silman AJ, Barnes C: Validation of the International Study Group criteria for Behçet’s disease. Br J Rheumatol 1994;33:115–117.
  4. Alpsoy E, Aktekin M, Er H, Durusoy C, Yilmaz E: Distribution and frequency of papulopustular lesions in Behçet’s disease: A randomized, controlled study. Int J Dermatol 1998;37:839–843.
  5. Zouboulis CC: Epidemiology of Adamantiades-Behçet’s disease. Ann Méd Interne 1999;150:488–498.
  6. Verity DH, Wallace GR, Seed PT, et al: Soluble adhesion molecules in Behçet’s disease. Ocul Immunol Inflamm 1998;6:81–92.

Article / Publication Details

First-Page Preview
Abstract of Clinical and Laboratory Investigation

Received: November 29, 2002
Accepted: May 10, 2003
Published online: January 29, 2004
Issue release date: 2003

Number of Print Pages: 3
Number of Figures: 0
Number of Tables: 2

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.